{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,5]],"date-time":"2025-11-05T06:42:10Z","timestamp":1762324930838,"version":"3.44.0"},"reference-count":127,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,4,9]],"date-time":"2022-04-09T00:00:00Z","timestamp":1649462400000},"content-version":"am","delay-in-days":404,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Therapies"],"published-print":{"date-parts":[[2021,3]]},"DOI":"10.1016\/j.therap.2021.02.001","type":"journal-article","created":{"date-parts":[[2021,2,4]],"date-time":"2021-02-04T16:50:58Z","timestamp":1612457458000},"page":"87-99","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"title":["Contributions of animal models of cognitive disorders to neuropsychopharmacology"],"prefix":"10.1016","volume":"76","author":[{"given":"Julie","family":"Deguil","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R\u00e9gis","family":"Bordet","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.therap.2021.02.001_bib0640","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1097\/JNN.0b013e3182829038","article-title":"Neurological and psychiatric diseases and their unique cognitive profiles: implications for nursing practice and research","volume":"45","author":"Vance","year":"2013","journal-title":"J Neurosci Nurs"},{"issue":"7","key":"10.1016\/j.therap.2021.02.001_bib0645","doi-asserted-by":"crossref","first-page":"1452","DOI":"10.1038\/sj.npp.1301285","article-title":"Abnormal neurotransmitter release underlying behavioral and cognitive disorders: toward concepts of dynamic and function-specific dysregulation","volume":"32","author":"Sarter","year":"2007","journal-title":"Neuropsychopharmacol"},{"issue":"3","key":"10.1016\/j.therap.2021.02.001_bib0650","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1007\/BF00426713","article-title":"Scopolamine induced learning failures in man","volume":"52","author":"Petersen","year":"1977","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.therap.2021.02.001_bib0655","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.conb.2014.06.004","article-title":"Neuromodulation by acetylcholine: examples from schizophrenia and depression","volume":"29","author":"Higley","year":"2014","journal-title":"Curr Opin Neurobiol"},{"issue":"3","key":"10.1016\/j.therap.2021.02.001_bib0660","doi-asserted-by":"crossref","first-page":"286","DOI":"10.2174\/157015908785777247","article-title":"Role of the central cholinergic system in the therapeutics of schizophrenia","volume":"6","author":"Terry","year":"2008","journal-title":"Curr Neuropharmacol"},{"key":"10.1016\/j.therap.2021.02.001_bib0665","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1016\/j.neubiorev.2015.05.011","article-title":"The muscarinic system, cognition and schizophrenia","volume":"55","author":"Carruthers","year":"2015","journal-title":"Neurosci Biobehav Rev"},{"issue":"6","key":"10.1016\/j.therap.2021.02.001_bib0670","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1001\/archpsyc.62.6.649","article-title":"Effects of cigarette smoking on spatial working memory and attentional deficits in schizophrenia: involvement of nicotinic receptor mechanisms","volume":"62","author":"Sacco","year":"2005","journal-title":"Arch Gen Psychiatry"},{"issue":"4","key":"10.1016\/j.therap.2021.02.001_bib0675","doi-asserted-by":"crossref","first-page":"403","DOI":"10.2174\/1570159X15666171103152136","article-title":"Cognitive effects of nicotine: recent progress","volume":"16","author":"Valentine","year":"2018","journal-title":"Curr Neuropharmacol"},{"issue":"7","key":"10.1016\/j.therap.2021.02.001_bib0680","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1016\/j.euroneuro.2014.03.011","article-title":"The effects of nicotine on cognition are dependent on baseline performance","volume":"24","author":"Niemegeers","year":"2014","journal-title":"Eur Neuropsychopharmacol"},{"issue":"1","key":"10.1016\/j.therap.2021.02.001_bib0685","doi-asserted-by":"crossref","first-page":"13158","DOI":"10.1038\/srep13158","article-title":"Distinct roles of basal forebrain cholinergic neurons in spatial and object recognition memory","volume":"5","author":"Oka","year":"2015","journal-title":"Sci Rep"},{"issue":"3","key":"10.1016\/j.therap.2021.02.001_bib0690","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1139\/y86-061","article-title":"Effects of altered cholinergic function on working and reference memory in the rat","volume":"64","author":"Beninger","year":"1986","journal-title":"Can J Physiol Pharmacol"},{"issue":"2","key":"10.1016\/j.therap.2021.02.001_bib0695","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1016\/0306-4522(87)90117-5","article-title":"Behavioural, biochemical and histochemical effects of different neurotoxic amino acids injected into nucleus basalis magnocellularis of rats","volume":"20","author":"Dunnet","year":"1987","journal-title":"Neuroscience"},{"issue":"1","key":"10.1016\/j.therap.2021.02.001_bib0700","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/0166-4328(88)90105-2","article-title":"Place navigation in rats is impaired by lesions of medial septum and diagonal band but not nucleus basalis magnocellularis","volume":"27","author":"Hagan","year":"1988","journal-title":"Behav Brain Res"},{"issue":"1","key":"10.1016\/j.therap.2021.02.001_bib0705","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/0006-8993(91)90863-Q","article-title":"Behavioral impairments after lesions of the nucleus basalis by ibotenic acid and quisqualic acid","volume":"555","author":"Connor","year":"1991","journal-title":"Brain Research"},{"issue":"3","key":"10.1016\/j.therap.2021.02.001_bib0710","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1016\/0306-4522(89)90290-X","article-title":"Comparison of behavioral effects of nucleus basalis magnocellularis lesions and somatosensory cortex ablation in the rat","volume":"32","author":"Wozniak","year":"1989","journal-title":"Neuroscience"},{"issue":"11","key":"10.1016\/j.therap.2021.02.001_bib0715","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1046\/j.1365-2362.1998.00393.x","article-title":"Scopolamine model of dementia: electroencephalogram findings and cognitive performance","volume":"28","author":"Ebert","year":"1998","journal-title":"Eur J Clin Invest"},{"issue":"8","key":"10.1016\/j.therap.2021.02.001_bib0720","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1016\/j.neubiorev.2010.04.001","article-title":"The validity of scopolamine as a pharmacological model for cognitive impairment: A review of animal behavioral studies","volume":"34","author":"Klinkenberg","year":"2010","journal-title":"Neurosci Biobehav Rev"},{"key":"10.1016\/j.therap.2021.02.001_bib0725","series-title":"Animal models of cognitive impairment","article-title":"Nicotinic receptor antagonists in rats","author":"Roegge","year":"2006"},{"issue":"8","key":"10.1016\/j.therap.2021.02.001_bib0730","doi-asserted-by":"crossref","first-page":"1676","DOI":"10.1111\/bcp.13268","article-title":"An anti-nicotinic cognitive challenge model using mecamylamine in comparison with the anti-muscarinic cognitive challenge using scopolamine","volume":"83","author":"Baakman","year":"2017","journal-title":"Br J Clin Pharmacol"},{"issue":"5","key":"10.1016\/j.therap.2021.02.001_bib0735","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1111\/bcp.13507","article-title":"Reversal of mecamylamine-induced effects in healthy subjects by nicotine receptor agonists: Cognitive and (electro) physiological responses: Mecamylamine effects reversal in healthy subjects","volume":"84","author":"Alvarez-Jimenez","year":"2018","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.therap.2021.02.001_bib0740","series-title":"Methods of behavior analysis in neuroscience","article-title":"The revival of scopolamine reversal for the assessment of cognition-enhancing drugs","author":"Buccafusco","year":"2009"},{"key":"10.1016\/j.therap.2021.02.001_bib0745","doi-asserted-by":"crossref","first-page":"91","DOI":"10.3389\/fpsyt.2018.00091","article-title":"Medications used for cognitive enhancement in patients with schizophrenia, bipolar disorder, Alzheimer's disease, and Parkinson's disease","volume":"9","author":"Hsu","year":"2018","journal-title":"Front Psychiatry"},{"issue":"3","key":"10.1016\/j.therap.2021.02.001_bib0750","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1093\/ntr\/nty034","article-title":"Alpha7 nicotinic receptors as therapeutic targets in schizophrenia","volume":"21","author":"Tregellas","year":"2019","journal-title":"Nicotine Tob Res"},{"issue":"8","key":"10.1016\/j.therap.2021.02.001_bib0755","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1111\/jphp.12919","article-title":"Muscarinic and nicotinic acetylcholine receptor agonists: current scenario in Alzheimer's disease therapy","volume":"70","author":"Verma","year":"2018","journal-title":"J Pharm Pharmacol"},{"key":"10.1016\/j.therap.2021.02.001_bib0760","doi-asserted-by":"crossref","first-page":"563","DOI":"10.3389\/fnins.2020.00563","article-title":"Efficacy of THN201, a combination of donepezil and mefloquine, to reverse neurocognitive deficits in Alzheimer's disease","volume":"14","author":"Droguerre","year":"2020","journal-title":"Front Neurosci"},{"key":"10.1016\/j.therap.2021.02.001_bib0765","doi-asserted-by":"crossref","first-page":"52","DOI":"10.3389\/fpsyt.2013.00052","article-title":"NMDA receptor activity in neuropsychiatric disorders","volume":"4","author":"Lakhan","year":"2013","journal-title":"Front Psychiatry"},{"issue":"17","key":"10.1016\/j.therap.2021.02.001_bib0770","doi-asserted-by":"crossref","first-page":"4254","DOI":"10.1111\/bph.13222","article-title":"Ketamine and phencyclidine: the good, the bad and the unexpected","volume":"172","author":"Lodge","year":"2015","journal-title":"Br J Pharmacol"},{"issue":"4","key":"10.1016\/j.therap.2021.02.001_bib0775","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1007\/s00213-006-0572-3","article-title":"Acute and chronic effects of ketamine upon human memory: a review","volume":"188","author":"Morgan","year":"2006","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.therap.2021.02.001_bib0780","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1196\/annals.1300.008","article-title":"receptor hypofunction model of psychosis","volume":"1003","author":"Farber","year":"2003","journal-title":"Ann N Y Acad Sci"},{"issue":"3","key":"10.1016\/j.therap.2021.02.001_bib0785","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1016\/j.pharmthera.2010.07.004","article-title":"Animal models of cognitive dysfunction and negative symptoms of schizophrenia: Focus on NMDA receptor antagonism","volume":"128","author":"Neill","year":"2010","journal-title":"Pharmacol Ther"},{"issue":"2","key":"10.1016\/j.therap.2021.02.001_bib0790","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1007\/s00213-011-2277-5","article-title":"A comparison of the effects of ketamine and phencyclidine with other antagonists of the NMDA receptor in rodent assays of attention and working memory","volume":"217","author":"Smith","year":"2011","journal-title":"Psychopharmacology (Berl)"},{"issue":"6","key":"10.1016\/j.therap.2021.02.001_bib0795","first-page":"573","article-title":"Role of the amygdala, hippocampus and entorhinal cortex in memory consolidation and expression","volume":"26","author":"Izquierdo","year":"1993","journal-title":"Braz J Med Biol Res"},{"key":"10.1016\/j.therap.2021.02.001_bib0800","doi-asserted-by":"crossref","first-page":"304","DOI":"10.3389\/fnbeh.2014.00304","article-title":"N-methyl-D-aspartate receptor-mediated glutamate transmission in nucleus accumbens plays a more important role than that in dorsal striatum in cognitive flexibility","volume":"8","author":"Ding","year":"2014","journal-title":"Front Behav Neurosci"},{"issue":"6","key":"10.1016\/j.therap.2021.02.001_bib0805","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1101\/lm.044750.116","article-title":"Medial prefrontal cortex and dorsomedial striatum are necessary for the trial-unique, delayed nonmatching-to-location (TUNL) task in rats: role of NMDA receptors","volume":"24","author":"Davies","year":"2017","journal-title":"Learn Mem"},{"issue":"2","key":"10.1016\/j.therap.2021.02.001_bib0810","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/j.bbr.2008.03.032","article-title":"MGlu5 antagonism impairs exploration and memory of spatial and non-spatial stimuli in rats","volume":"191","author":"Christoffersen","year":"2008","journal-title":"Behavi Brain Res"},{"issue":"1\u20133","key":"10.1016\/j.therap.2021.02.001_bib0815","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.ejphar.2012.04.013","article-title":"A novel glycine transporter-1 (GlyT1) inhibitor, ASP2535 (4-[3-isopropyl-5-(6-phenyl-3-pyridyl)-4H-1,2,4-triazol-4-yl]-2,1,3-benzoxadiazole), improves cognition in animal models of cognitive impairment in schizophrenia and Alzheimer's disease","volume":"685","author":"Harada","year":"2012","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.therap.2021.02.001_bib0820","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/j.pnpbp.2019.02.001","article-title":"The glycine site of NMDA receptors: A target for cognitive enhancement in psychiatric disorders","volume":"92","author":"Peyrovian","year":"2019","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"issue":"213","key":"10.1016\/j.therap.2021.02.001_bib0825","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1007\/978-3-642-25758-2_12","article-title":"Glycine transport inhibitors in the treatment of schizophrenia","author":"Javitt","year":"2012","journal-title":"Handb Exp Pharmacol"},{"issue":"10","key":"10.1016\/j.therap.2021.02.001_bib0830","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1038\/mp.2015.68","article-title":"Effects of glutamate positive modulators on cognitive deficits in schizophrenia: a systematic review and meta-analysis of double-blind randomized controlled trials","volume":"20","author":"Iwata","year":"2015","journal-title":"Mol Psychiatry"},{"issue":"5","key":"10.1016\/j.therap.2021.02.001_bib0835","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1111\/j.1472-8206.2012.01045.x","article-title":"Therapeutic effects of metabotropic glutamate receptor 5 positive allosteric modulator CDPPB on phencyclidine-induced cognitive deficits in mice","volume":"27","author":"Horio","year":"2013","journal-title":"Fundam Clin Pharmacol"},{"issue":"1","key":"10.1016\/j.therap.2021.02.001_bib0840","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1007\/s00213-014-3653-8","article-title":"mGluR5 positive allosteric modulation and its effects on MK-801 induced set-shifting impairments in a rat operant delayed matching\/non-matching-to-sample task","volume":"232","author":"LaCrosse","year":"2015","journal-title":"Psychopharmacology"},{"issue":"6","key":"10.1016\/j.therap.2021.02.001_bib0845","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1111\/bph.12230","article-title":"The kynurenine pathway as a therapeutic target in cognitive and neurodegenerative disorders","volume":"169","author":"Stone","year":"2013","journal-title":"Br J Pharmacol"},{"issue":"6","key":"10.1016\/j.therap.2021.02.001_bib0850","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1016\/S0028-3908(99)00019-2","article-title":"Memantine is a clinically well tolerated N-methyl-D-aspartate (NMDA) receptor antagonist--a review of preclinical data","volume":"38","author":"Parsons","year":"1999","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.therap.2021.02.001_bib0855","doi-asserted-by":"crossref","first-page":"73","DOI":"10.3389\/fphar.2019.00073","article-title":"Cognitive enhancer effects of low memantine doses are facilitated by an alpha7 nicotinic acetylcholine receptor agonist in scopolamine-induced amnesia in rats","volume":"10","author":"Bali","year":"2019","journal-title":"Front Pharmacol"},{"issue":"2","key":"10.1016\/j.therap.2021.02.001_bib0860","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/0301-0082(90)90003-Y","article-title":"MPTP-induced parkinsonism","volume":"34","author":"Stern","year":"1990","journal-title":"Progr Neurobiol"},{"key":"10.1016\/j.therap.2021.02.001_bib0865","doi-asserted-by":"crossref","first-page":"14002","DOI":"10.1038\/npjschz.2014.2","article-title":"The relationship between dopamine receptor D1 and cognitive performance","volume":"1","author":"Tsang","year":"2015","journal-title":"NPJ Schizophr"},{"key":"10.1016\/j.therap.2021.02.001_bib0870","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.brainres.2018.03.035","article-title":"Limitations of the rat medial forebrain lesion model to study prefrontal cortex mediated cognitive tasks in Parkinson's disease","volume":"1702","author":"Marshall","year":"2019","journal-title":"Brain Research"},{"issue":"10","key":"10.1016\/j.therap.2021.02.001_bib0875","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1101\/lm.032029.113","article-title":"Understanding cognitive deficits in Parkinson's disease: lessons from preclinical animal models","volume":"20","author":"Solari","year":"2013","journal-title":"Lear Mem"},{"issue":"11","key":"10.1016\/j.therap.2021.02.001_bib0880","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1093\/cercor\/11.11.1015","article-title":"Differential effects of 6-OHDA lesions of the frontal cortex and caudate nucleus on the ability to acquire an attentional set","volume":"11","author":"Crofts","year":"2001","journal-title":"Cereb Cortex"},{"issue":"3","key":"10.1016\/j.therap.2021.02.001_bib0885","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1007\/s00213-013-3158-x","article-title":"Effects of the adenosine A2A antagonist istradefylline on cognitive performance in rats with a 6-OHDA lesion in prefrontal cortex","volume":"230","author":"Kadowaki Horita","year":"2013","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.therap.2021.02.001_bib0890","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1038\/s41380-018-0312-1","article-title":"D1 dopamine receptors\u00a0intrinsic activity and functional selectivity affect working memory in prefrontal cortex","volume":"26","author":"Yang","year":"2021","journal-title":"Mol Psychiatry"},{"key":"10.1016\/j.therap.2021.02.001_bib0895","doi-asserted-by":"crossref","first-page":"62","DOI":"10.3389\/fnins.2013.00062","article-title":"Prefrontal dopamine and behavioral flexibility: shifting from an \u00ab\u00a0inverted-U\u00a0\u00bb toward a family of functions","volume":"7","author":"Floresco","year":"2013","journal-title":"Front Neurosci"},{"issue":"1","key":"10.1016\/j.therap.2021.02.001_bib0900","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/j.neuroscience.2005.09.028","article-title":"Under the curve: critical issues for elucidating D1 receptor function in working memory","volume":"139","author":"Williams","year":"2006","journal-title":"Neuroscience"},{"key":"10.1016\/j.therap.2021.02.001_bib0905","doi-asserted-by":"crossref","first-page":"666","DOI":"10.3389\/fphar.2017.00666","article-title":"The dopamine D5 receptor is involved in working memory","volume":"8","author":"Carr","year":"2017","journal-title":"Front Pharmacol"},{"issue":"5","key":"10.1016\/j.therap.2021.02.001_bib0910","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1093\/ijnp\/pyaa007","article-title":"A neurofunctional domains approach to evaluate D1\/D5 dopamine receptor partial agonism on cognition and motivation in healthy volunteers with low working memory capacity","volume":"23","author":"Balice-Gordon","year":"2020","journal-title":"Int J Neuropsychopharmacol"},{"issue":"3\u20134","key":"10.1016\/j.therap.2021.02.001_bib0915","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1007\/s00213-002-1154-7","article-title":"The 5-choice serial reaction time task: behavioural pharmacology and functional neurochemistry","volume":"163","author":"Robbins","year":"2002","journal-title":"Psychopharmacology (Berl)"},{"issue":"8","key":"10.1016\/j.therap.2021.02.001_bib0920","doi-asserted-by":"crossref","first-page":"2921","DOI":"10.1523\/JNEUROSCI.17-08-02921.1997","article-title":"Activation of glutamatergic neurotransmission by ketamine: a novel step in the pathway from NMDA receptor blockade to dopaminergic and cognitive disruptions associated with the prefrontal cortex","volume":"17","author":"Moghaddam","year":"1997","journal-title":"J Neurosci"},{"issue":"3","key":"10.1016\/j.therap.2021.02.001_bib0925","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1007\/s00213-010-1840-9","article-title":"Amelioration of ketamine-induced working memory deficits by dopamine D1 receptor agonists","volume":"210","author":"Roberts","year":"2010","journal-title":"Psychopharmacology (Berl)"},{"issue":"4","key":"10.1016\/j.therap.2021.02.001_bib0930","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1002\/mds.27962","article-title":"NYX-458 Improves cognitive performance in a primate Parkinson's disease model","volume":"35","author":"Barth","year":"2020","journal-title":"Mov Disord"},{"key":"10.1016\/j.therap.2021.02.001_bib0935","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1016\/j.bbr.2014.10.030","article-title":"Differential effects of \u03b17 nicotinic receptor agonist PHA-543613 on spatial memory performance of rats in two distinct pharmacological dementia models","volume":"278","author":"Bali","year":"2015","journal-title":"Behav Brain Res"},{"key":"10.1016\/j.therap.2021.02.001_bib0940","doi-asserted-by":"crossref","first-page":"112946","DOI":"10.1016\/j.bbr.2020.112946","article-title":"\u03b17 nicotinic receptor agonist and positive allosteric modulators differently improved schizophrenia-like cognitive deficits in male rats","volume":"397","author":"Unal","year":"2021","journal-title":"Behav Brain Res"},{"issue":"4","key":"10.1016\/j.therap.2021.02.001_bib0945","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1038\/mp.2016.53","article-title":"Methylomic changes during conversion to psychosis","volume":"22","author":"Kebir","year":"2017","journal-title":"Mol Psychiatry"},{"issue":"3","key":"10.1016\/j.therap.2021.02.001_bib0950","doi-asserted-by":"crossref","first-page":"273","DOI":"10.2174\/1570159X1203140511160832","article-title":"Evidence for an immune role on cognition in schizophrenia: a systematic review","volume":"12","author":"Ribeiro-Santos","year":"2014","journal-title":"Curr Neuropharmacol"},{"issue":"3","key":"10.1016\/j.therap.2021.02.001_bib0955","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/j.neubiorev.2008.10.005","article-title":"Evidence for a cytokine model of cognitive function","volume":"33","author":"McAfoose","year":"2009","journal-title":"Neurosci Biobehav Rev"},{"issue":"1","key":"10.1016\/j.therap.2021.02.001_bib0960","doi-asserted-by":"crossref","first-page":"5790","DOI":"10.1038\/s41598-019-42286-8","article-title":"Neuroinflammation induced by lipopolysaccharide causes cognitive impairment in mice","volume":"9","author":"Zhao","year":"2019","journal-title":"Sci Rep"},{"issue":"12","key":"10.1016\/j.therap.2021.02.001_bib0965","doi-asserted-by":"crossref","first-page":"2106","DOI":"10.1007\/s12272-015-0648-x","article-title":"Involvement of inflammation in Alzheimer's disease pathogenesis and therapeutic potential of anti-inflammatory agents","volume":"38","author":"Shadfar","year":"2015","journal-title":"Arch Pharm Res"},{"issue":"1","key":"10.1016\/j.therap.2021.02.001_bib0970","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1186\/s12974-019-1417-4","article-title":"Anti-inflammatory and cognitive effects of interferon-\u03b21a (IFN\u03b21a) in a rat model of Alzheimer's disease","volume":"16","author":"Mud\u00f2","year":"2019","journal-title":"J Neuroinflammation"},{"issue":"1","key":"10.1016\/j.therap.2021.02.001_bib0975","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1186\/s12974-018-1141-5","article-title":"Galantamine improves cognition, hippocampal inflammation, and synaptic plasticity impairments induced by lipopolysaccharide in mice","volume":"15","author":"Liu","year":"2018","journal-title":"J Neuroinflammation"},{"issue":"5","key":"10.1016\/j.therap.2021.02.001_bib0980","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1007\/s00213-015-4169-6","article-title":"Minocycline protects against lipopolysaccharide-induced cognitive impairment in mice","volume":"233","author":"Hou","year":"2016","journal-title":"Psychopharmacology (Berl)"},{"issue":"8","key":"10.1016\/j.therap.2021.02.001_bib0985","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1177\/0004867419835028","article-title":"Adjunctive use of anti-inflammatory drugs for schizophrenia: A meta-analytic investigation of randomized controlled trials","volume":"53","author":"Cho","year":"2019","journal-title":"Aust N Z J Psychiatry"},{"issue":"2","key":"10.1016\/j.therap.2021.02.001_bib0990","first-page":"164","article-title":"Minocycline at 2 different dosages vs placebo for patients with mild Alzheimer disease: A randomized clinical trial. JAMA Neurol","volume":"77","author":"Howard","year":"2020"},{"issue":"20","key":"10.1016\/j.therap.2021.02.001_bib0995","doi-asserted-by":"crossref","first-page":"2960","DOI":"10.2174\/1381612822666160307145931","article-title":"Association of oxidative stress with psychiatric disorders","volume":"22","author":"Hassan","year":"2016","journal-title":"Curr Pharm Des"},{"issue":"1","key":"10.1016\/j.therap.2021.02.001_bib1000","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1124\/jpet.116.237503","article-title":"Oxidative stress and the central nervous system","volume":"360","author":"Salim","year":"2017","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.therap.2021.02.001_bib1005","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/j.freeradbiomed.2018.09.033","article-title":"Striking while the iron is hot: Iron metabolism and ferroptosis in neurodegeneration","volume":"133","author":"Masaldan","year":"2019","journal-title":"Free Radic Biol Med"},{"issue":"4","key":"10.1016\/j.therap.2021.02.001_bib1010","doi-asserted-by":"crossref","first-page":"797","DOI":"10.3233\/JAD-121996","article-title":"Role of brain iron accumulation in cognitive dysfunction: evidence from animal models and human studies","volume":"34","author":"Schr\u00f6der","year":"2013","journal-title":"J Alzheimers Dis"},{"issue":"11","key":"10.1016\/j.therap.2021.02.001_bib1015","doi-asserted-by":"crossref","first-page":"2932","DOI":"10.1038\/s41380-019-0375-7","article-title":"Brain iron is associated with accelerated cognitive decline in people with Alzheimer pathology","volume":"25","author":"Ayton","year":"2020","journal-title":"Mol Psychiatry"},{"issue":"8","key":"10.1016\/j.therap.2021.02.001_bib1020","doi-asserted-by":"crossref","first-page":"2112","DOI":"10.1093\/brain\/awx137","article-title":"Cerebral quantitative susceptibility mapping predicts amyloid-\u03b2-related cognitive decline","volume":"140","author":"Ayton","year":"2017","journal-title":"Brain"},{"key":"10.1016\/j.therap.2021.02.001_bib1025","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1016\/j.fct.2019.05.038","article-title":"Long-term iron exposure causes widespread molecular alterations associated with memory impairment in mice","volume":"130","author":"Wang","year":"2019","journal-title":"Food Chem Toxicol"},{"key":"10.1016\/j.therap.2021.02.001_bib1030","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1016\/j.csbj.2019.02.004","article-title":"Psychiatric disorders and oxidative injury: antioxidant effects of zolpidem therapy disclosed in silico","volume":"17","author":"Bortoli","year":"2019","journal-title":"Comput Struct Biotechnol J"},{"key":"10.1016\/j.therap.2021.02.001_bib1035","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.neubiorev.2017.04.013","article-title":"The effect of N-acetylcysteine (NAC) on human cognition \u2013 A systematic review","volume":"78","author":"Skvarc","year":"2017","journal-title":"Neurosci Biobehav Rev"},{"issue":"2","key":"10.1016\/j.therap.2021.02.001_bib1040","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1080\/1028415X.2018.1478766","article-title":"Improvement of cognitive function in schizophrenia with N-acetylcysteine: A theoretical review","volume":"23","author":"Yolland","year":"2020","journal-title":"Nutr Neurosci"},{"issue":"2\u20133","key":"10.1016\/j.therap.2021.02.001_bib1045","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1007\/s12017-017-8447-9","article-title":"Deferiprone rescues behavioral deficits induced by mild iron exposure in a mouse model of alpha-synuclein aggregation","volume":"19","author":"Carboni","year":"2017","journal-title":"Neuromolecular Med"},{"key":"10.1016\/j.therap.2021.02.001_bib1050","doi-asserted-by":"crossref","first-page":"112314","DOI":"10.1016\/j.bbr.2019.112314","article-title":"Deferiprone ameliorates memory impairment in Scopolamine-treated rats: The impact of its iron-chelating effect on \u03b2-amyloid disposition","volume":"378","author":"Fawzi","year":"2020","journal-title":"Behav Brain Res"},{"issue":"4","key":"10.1016\/j.therap.2021.02.001_bib1055","doi-asserted-by":"crossref","first-page":"109","DOI":"10.3390\/ph11040109","article-title":"New perspectives in iron chelation therapy for the treatment of neurodegenerative diseases","volume":"11","author":"Nu\u00f1ez","year":"2018","journal-title":"Pharmaceuticals (Basel)"},{"issue":"2","key":"10.1016\/j.therap.2021.02.001_bib1060","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/j.bj.2020.01.001","article-title":"Brain-derived neurotrophic factor and mental disorders","volume":"43","author":"Lin","year":"2020","journal-title":"Biomed J"},{"key":"10.1016\/j.therap.2021.02.001_bib1065","doi-asserted-by":"crossref","first-page":"156","DOI":"10.3389\/fnmol.2018.00156","article-title":"Critical issues in BDNF Val66Met genetic studies of neuropsychiatric disorders","volume":"11","author":"Tsai","year":"2018","journal-title":"Front Mol Neurosci"},{"key":"10.1016\/j.therap.2021.02.001_bib1070","doi-asserted-by":"crossref","first-page":"2905","DOI":"10.2147\/NDT.S116287","article-title":"Increased miR-132 level is associated with visual memory dysfunction in patients with depression","volume":"12","author":"Liu","year":"2016","journal-title":"Neuropsychiatr Dis Treat"},{"key":"10.1016\/j.therap.2021.02.001_bib1075","doi-asserted-by":"crossref","first-page":"363","DOI":"10.3389\/fncel.2019.00363","article-title":"Brain-derived neurotrophic factor: a key molecule for memory in the healthy and the pathological brain","volume":"13","author":"Miranda","year":"2019","journal-title":"Front Cell Neurosci"},{"issue":"4","key":"10.1016\/j.therap.2021.02.001_bib1080","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1038\/sj.mp.4001637","article-title":"BDNF in schizophrenia, depression and corresponding animal models","volume":"10","author":"Angelucci","year":"2005","journal-title":"Mol Psychiatry"},{"key":"10.1016\/j.therap.2021.02.001_bib1085","doi-asserted-by":"crossref","first-page":"22","DOI":"10.3389\/neuro.02.022.2009","article-title":"The use of lentiviral vectors and Cre\/loxP to investigate the function of genes in complex behaviors","volume":"2","author":"Heldt","year":"2009","journal-title":"Front Mol Neurosci"},{"key":"10.1016\/j.therap.2021.02.001_bib1090","doi-asserted-by":"crossref","first-page":"143","DOI":"10.3389\/fnbeh.2014.00143","article-title":"Mice with altered BDNF signaling as models for mood disorders and antidepressant effects","volume":"8","author":"Lindholm","year":"2014","journal-title":"Front Behav Neurosci"},{"issue":"8","key":"10.1016\/j.therap.2021.02.001_bib1095","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1080\/14712598.2016.1183641","article-title":"producing cells as a potential treatment for neurologic disease","volume":"16","author":"Deng","year":"2016","journal-title":"Expert Opin Biol Ther"},{"key":"10.1016\/j.therap.2021.02.001_bib1100","doi-asserted-by":"crossref","first-page":"163","DOI":"10.3389\/fnbeh.2019.00163","article-title":"Risperidone reverses the downregulation of BDNF in hippocampal neurons and MK801-induced cognitive impairment in rats","volume":"13","author":"Yu","year":"2019","journal-title":"Front Behav Neurosci"},{"issue":"6","key":"10.1016\/j.therap.2021.02.001_bib1105","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1038\/sj.npp.1300669","article-title":"Reversal of clozapine effects on working memory in rats with fimbria-fornix lesions","volume":"30","author":"Addy","year":"2005","journal-title":"Neuropsychopharmacology"},{"issue":"3","key":"10.1016\/j.therap.2021.02.001_bib1110","doi-asserted-by":"crossref","first-page":"279","DOI":"10.9758\/cpn.2016.14.3.279","article-title":"Differential effects of olanzapine and haloperidol on MK-801-induced memory impairment in mice","volume":"14","author":"Song","year":"2016","journal-title":"Clin Psychopharmacol Neurosci"},{"key":"10.1016\/j.therap.2021.02.001_bib1115","doi-asserted-by":"crossref","first-page":"6490652","DOI":"10.1155\/2017\/6490652","article-title":"Prevention of memory impairment and neurotrophic factors increased by lithium in Wistar rats submitted to pneumococcal meningitis model","volume":"2017","author":"Sim\u00f5es","year":"2017","journal-title":"Mediators Inflamm"},{"issue":"2","key":"10.1016\/j.therap.2021.02.001_bib1120","doi-asserted-by":"crossref","first-page":"233","DOI":"10.9758\/cpn.2019.17.2.233","article-title":"Effects of chronic and acute lithium treatment on the long-term potentiation and spatial memory in adult rats","volume":"17","author":"Yousef","year":"2019","journal-title":"Clin Psychopharmacol Neurosci"},{"issue":"1","key":"10.1016\/j.therap.2021.02.001_bib1125","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1038\/sj.npp.1301571","article-title":"Interaction between BDNF and serotonin: role in mood disorders","volume":"33","author":"Martinowich","year":"2008","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.therap.2021.02.001_bib1130","doi-asserted-by":"crossref","first-page":"11","DOI":"10.4137\/DTI.S13870","article-title":"The antidepressant agomelatine improves memory deterioration and upregulates CREB and BDNF gene expression levels in unpredictable chronic mild stress (UCMS)-exposed mice","volume":"8","author":"Gumuslu","year":"2014","journal-title":"Drug Target Insights"},{"issue":"12","key":"10.1016\/j.therap.2021.02.001_bib1135","doi-asserted-by":"crossref","first-page":"4906","DOI":"10.1073\/pnas.0811228106","article-title":"with an ampakine rescues synaptic plasticity and memory in Huntington's disease knockin mice","volume":"106","author":"Simmons","year":"2009","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"4","key":"10.1016\/j.therap.2021.02.001_bib1140","doi-asserted-by":"crossref","first-page":"C743","DOI":"10.1152\/ajpcell.00019.2011","article-title":"Hypoxia. 3. Hypoxia and neurotransmitter synthesis","volume":"300","author":"Kumar","year":"2011","journal-title":"Am J Physiol Cell Physiol"},{"issue":"4","key":"10.1016\/j.therap.2021.02.001_bib1145","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1111\/j.1471-4159.1973.tb07522.x","article-title":"The effect of hypoxia on monoamine synthesis, levels and metabolism in rat brain","volume":"21","author":"Davis","year":"1973","journal-title":"J Neurochem"},{"issue":"3","key":"10.1016\/j.therap.2021.02.001_bib1150","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1016\/S0163-1047(05)80023-8","article-title":"Hypobaric hypoxia impairs spatial memory in an elevation-dependent fashion","volume":"62","author":"Shukitt-Hale","year":"1994","journal-title":"Behav Neural Biol"},{"issue":"3","key":"10.1016\/j.therap.2021.02.001_bib1155","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1213\/01.ane.0000265555.57472.49","article-title":"Physostigmine reverses cognitive dysfunction caused by moderate hypoxia in adult mice","volume":"105","author":"Bekker","year":"2007","journal-title":"Anesth Analg"},{"issue":"1","key":"10.1016\/j.therap.2021.02.001_bib1160","first-page":"104","article-title":"Neurochemicals and behavioural alterations in sleep deprivation: a revisit","volume":"1","author":"Parameswari","year":"2017","journal-title":"J Dement"},{"issue":"7\u20138","key":"10.1016\/j.therap.2021.02.001_bib1165","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1007\/s00018-007-6457-8","article-title":"Effects of sleep deprivation on neural functioning: an integrative review","volume":"64","author":"Boonstra","year":"2007","journal-title":"Cell Mol Life Sci"},{"issue":"1","key":"10.1016\/j.therap.2021.02.001_bib1170","doi-asserted-by":"crossref","first-page":"7","DOI":"10.5114\/biolsport.2020.89936","article-title":"One night of sleep deprivation impairs executive function but does not affect psychomotor or motor performance","volume":"37","author":"Skurvydas","year":"2020","journal-title":"Biol Sport"},{"key":"10.1016\/j.therap.2021.02.001_bib1175","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/B978-0-444-53702-7.00007-5","article-title":"Effects of sleep deprivation on cognition","volume":"185","author":"Killgore","year":"2010","journal-title":"Prog Brain Res"},{"key":"10.1016\/j.therap.2021.02.001_bib1180","doi-asserted-by":"crossref","first-page":"106","DOI":"10.3389\/fnsys.2013.00106","article-title":"Experimental sleep deprivation as a tool to test memory deficits in rodents","volume":"7","author":"Colavito","year":"2013","journal-title":"Front Syst Neurosci"},{"issue":"3","key":"10.1016\/j.therap.2021.02.001_bib1185","doi-asserted-by":"crossref","first-page":"231","DOI":"10.2174\/1570159X11311030001","article-title":"Neurobiological consequences of sleep deprivation","volume":"11","author":"Alkadhi","year":"2013","journal-title":"Curr Neuropharmacol"},{"issue":"1","key":"10.1016\/j.therap.2021.02.001_bib1190","doi-asserted-by":"crossref","first-page":"05","DOI":"10.31491\/APT.2019.12.002","article-title":"Sleep-deprived cognitive impairment in aging mice is alleviated by rapamycin","volume":"1","author":"Mukherjeea","year":"2019","journal-title":"APT"},{"key":"10.1016\/j.therap.2021.02.001_bib1195","doi-asserted-by":"crossref","first-page":"235","DOI":"10.3389\/fneur.2017.00235","article-title":"Neural consequences of chronic short sleep: reversible or lasting?","volume":"8","author":"Zhao","year":"2017","journal-title":"Front Neurol"},{"key":"10.1016\/j.therap.2021.02.001_bib1200","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1016\/j.ynstr.2014.10.008","article-title":"Glucocorticoid mechanisms of functional connectivity changes in stress-related neuropsychiatric disorders","volume":"1","author":"Hall","year":"2015","journal-title":"Neurobiol Stress"},{"issue":"6","key":"10.1016\/j.therap.2021.02.001_bib1205","first-page":"241","volume":"17","author":"Freeman","year":"2014","journal-title":"Granholm A-C. Damaging effects of a high-fat diet to the brain and cognition: a review of proposed mechanisms. Nutr Neurosci"},{"key":"10.1016\/j.therap.2021.02.001_bib1210","doi-asserted-by":"crossref","first-page":"509","DOI":"10.3389\/fncel.2019.00509","article-title":"High-fat diet induces neuroinflammation and mitochondrial impairment in mice cerebral cortex and synaptic fraction","volume":"13","author":"Cavaliere","year":"2019","journal-title":"Front Cell Neurosci"},{"issue":"11","key":"10.1016\/j.therap.2021.02.001_bib1215","doi-asserted-by":"crossref","first-page":"2579","DOI":"10.3390\/nu11112579","article-title":"Effect of high-fat diets on oxidative stress, cellular inflammatory response and cognitive function","volume":"11","author":"Tan","year":"2019","journal-title":"Nutrients"},{"issue":"10","key":"10.1016\/j.therap.2021.02.001_bib1220","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.3390\/antiox9101018","article-title":"Neural underpinnings of obesity: the role of oxidative stress and inflammation in the brain","volume":"9","author":"Mullins","year":"2020","journal-title":"Antioxidants (Basel)"},{"issue":"3","key":"10.1016\/j.therap.2021.02.001_bib1225","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1016\/j.neurobiolaging.2014.09.028","article-title":"Central activation of PPAR-gamma ameliorates diabetes induced cognitive dysfunction and improves BDNF expression","volume":"36","author":"Kariharan","year":"2015","journal-title":"Neurobiol Aging"},{"issue":"3","key":"10.1016\/j.therap.2021.02.001_bib1230","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1016\/j.pharep.2013.11.002","article-title":"Telmisartan attenuates cognitive impairment caused by chronic stress in rats","volume":"66","author":"Wincewicz","year":"2014","journal-title":"Pharmacol Rep"},{"issue":"5","key":"10.1016\/j.therap.2021.02.001_bib1235","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1111\/acps.12799","article-title":"The effect of adjunctive telmisartan treatment on psychopathology and cognition in patients with schizophrenia","volume":"136","author":"Fan","year":"2017","journal-title":"Acta Psychiatr Scand"},{"key":"10.1016\/j.therap.2021.02.001_bib1240","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/j.nlm.2014.10.011","article-title":"PDE and cognitive processing: beyond the memory domain","volume":"119","author":"Heckman","year":"2015","journal-title":"Neurobiol Learn Mem"},{"issue":"2","key":"10.1016\/j.therap.2021.02.001_bib1245","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1016\/j.neurobiolaging.2014.08.028","article-title":"Inhibition of phosphodiesterase 2 reverses impaired cognition and neuronal remodeling caused by chronic stress","volume":"36","author":"Xu","year":"2015","journal-title":"Neurobiol Aging"},{"key":"10.1016\/j.therap.2021.02.001_bib1250","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.neuropharm.2012.06.048","article-title":"Chronic phosphodiesterase type 2 inhibition improves memory in the APPswe\/PS1dE9 mouse model of Alzheimer's disease","volume":"64","author":"Sierksma","year":"2013","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.therap.2021.02.001_bib1255","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.brainres.2008.02.108","article-title":"The effect of selective inhibition of cyclic GMP hydrolyzing phosphodiesterases 2 and 5 on learning and memory processes and nitric oxide synthase activity in brain during aging","volume":"1216","author":"Domek-\u0141opaci\u0144ska","year":"2008","journal-title":"Brain Res"},{"issue":"7","key":"10.1016\/j.therap.2021.02.001_bib1260","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1016\/j.neuropharm.2004.07.040","article-title":"Inhibition of phosphodiesterase 2 increases neuronal cGMP, synaptic plasticity and memory performance","volume":"47","author":"Boess","year":"2004","journal-title":"Neuropharmacology"},{"issue":"9","key":"10.1016\/j.therap.2021.02.001_bib1265","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1080\/13543784.2017.1364360","article-title":"Investigational phosphodiesterase inhibitors in phase I and phase II clinical trials for Alzheimer's disease","volume":"26","author":"Prickaerts","year":"2017","journal-title":"Expert Opin Investig Drugs"},{"issue":"1","key":"10.1016\/j.therap.2021.02.001_bib1270","doi-asserted-by":"crossref","first-page":"185","DOI":"10.3233\/ADR-200191","article-title":"Phosphodiesterase inhibitors for Alzheimer's disease: A systematic review of clinical trials and epidemiology with a mechanistic rationale","volume":"4","author":"Sanders","year":"2020","journal-title":"J Alzheimers Dis Rep"}],"container-title":["Therapies"],"original-title":[],"language":"fr","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0040595721000688?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0040595721000688?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,22]],"date-time":"2025-09-22T18:55:13Z","timestamp":1758567313000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0040595721000688"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3]]},"references-count":127,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2021,3]]}},"alternative-id":["S0040595721000688"],"URL":"https:\/\/doi.org\/10.1016\/j.therap.2021.02.001","relation":{},"ISSN":["0040-5957"],"issn-type":[{"type":"print","value":"0040-5957"}],"subject":[],"published":{"date-parts":[[2021,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Contributions of animal models of cognitive disorders to neuropsychopharmacology","name":"articletitle","label":"Article Title"},{"value":"Therapies","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.therap.2021.02.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Soci\u00e9t\u00e9 fran\u00e7aise de pharmacologie et de th\u00e9rapeutique. Published by Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}]}}